Post-marketing Surveillance for the Clinical Safety and Effectiveness of Eribulin Mesylate in Patients With Inoperable or Recurrent Breast Cancer (Study HAL01S)

NCT01463891 · clinicaltrials.gov ↗
COMPLETED
Status
963
Enrollment
INDUSTRY
Sponsor class

Conditions

Interventions

Sponsor

Eisai Co., Ltd.